Xanthine Oxidase and Uric Acid Origin in Preeclamptic Women

• Conditions: Hyperuricemia; Pre-Eclampsia
• Interventions: Other: No intervention

• Registration Number: NCT04463940
• Lead Sponsor: Barzilai Medical Center

Brief Summary

Findings regarding the presence of xanthine oxidase and uric acid in different blood locations is important in preeclamptic women. We aim to detecting Xanthine oxidase and uric acid levels in both umbilical cord artery and vein as well as maternal blood (3 "locations") in pregnant women with and without diagnosis of preeclampsia. The study population will be divided into groups matching the three "locations" in order to describe and compare outcome levels.

Detailed Description

Significance - findings regarding the presence of xanthine oxidase and uric acid in different blood locations may provide a scientific basis for understanding the source of them in preeclamptic women. Aim - detecting Xanthine oxidase and uric acid levels in both umbilical cord artery and vein as well as maternal blood (3 "locations"). Methods - samples will be collected from pregnant women with and without diagnosis of preeclampsia with blood uric acid \> 6 mg/dL. Than the study population will be divided into groups matching the three "locations". The investigators will describe and compare outcome levels (including Xanthine oxidase, uric acid).

Study Timeline

• Study First Submitted: 2020-06-08
• Study Start: 2020-06-30
• Study First Submitted QC: 2020-07-08
• Study First Posted: 2020-07-09
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-20
• Last Update Posted: 2022-07-25
• Primary Completion: 2023-08
• Study Completion: 2024-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

• preeclampsia and none-preeclampsia diagnosed pregnant women.

Exclusion Criteria

• Known or reported kidney disease.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Maternal blood	No intervention	participant's blood will be obtained
Umbilical cord venus blood	No intervention	participant's umbilical cord Venus blood will be obtained
Umbilical cord arterial blood	No intervention	participant's umbilical cord arterial blood will be obtained

Primary Outcome Measures

Name	Time	Method
Uric Acid	through study completion, an average of 1 year	mg/dL

Trial Locations

Locations (1)

Barzilai Medical Center; 🇮🇱 Ashkelon, Israel